Julien TorgueScientific Director AREVA Med
Masahiko TokuraRIT Development Fujifilm RI Pharma
Dragan CicicCOO & CMO Actinium Pharmaceuticals
John BabichPresident & CSO Molecular Insight Pharmaceuticals
Recent improvements in tumour targeting, drug delivery and the use of alpha emitters has led to a host of clinical trials with radioimmunoconjugates taking place across a range of cancer indications. But to fulfil their true promise, these exciting therapies must navigate the clinic successfully.
Designed by the world’s leading clinical and technical experts, EMIT: Targeted Radiotherapy is the only industry forum dedicated to accelerating the clinical development of targeted radiotherapies.
Attend and you’ll get unparalleled insights into how to optimize your dosimetry, incorporate companion imaging agents, identify and mitigate for adverse events and boost efficacy effectively through drug combinations.
If you want to progress your targeted radiotherapy from the lab to the clinic and on to the market then this is a must attend meeting.
Download the final brochure now for all the meeting information.
For more information on what will be covered in the meeting, including the final speaker line up, agenda and workshop details, please download the brochure.
Who should attend:
How can you get involved?
"Excellent – Congratulations!" Immunomedics
"The quality of the speaker was superb. They represent the major world leaders in the science of medical radioimmunotherapy. The program was also comprehensive, focusing on each technical area of importance, which, taken together, composes the field. The intimate setting of the conference facilitated professional interactions and networking." Pacific Northwest National Laboratory
"Very informative. Greatly facilitated networking and interaction with representatives of academia and industry." NCI
"Excellent program highlighting cutting edge work in the field. Innovative approach to meeting structure – networking and brainstorming activities were fun and useful." Novelos Therapeutics